Desjardins
Desjardins Group is a financial services cooperative that provides a comprehensive array of personal and business services. For individuals, it offers products such as credit and prepaid cards, personal and auto loans, insurance, and investment options. Businesses benefit from services that include financing solutions, insurance, payroll management, and international cash management. Additionally, Desjardins Securities provides a full suite of securities brokerage services, catering to both individual investors and institutional clients through various investment products and advisory services. Its venture capital division manages a range of funds, including Desjardins Venture Capital and Capital régional et coopératif Desjardins, aiming to support businesses with financial resources and expertise. Through these diverse offerings, Desjardins Group plays a significant role in the financial ecosystem, addressing the needs of both personal and commercial clients.
Artis is a diversified Canadian real estate investment trust investing in industrial and office properties in Canada and the United States. Since 2004, Artis has executed an aggressive but disciplined growth strategy, building a portfolio of commercial properties in select markets in Canada and the United States. As of September 30, 2020, Artis' commercial property comprises approximately 23.8 million square feet of leasable area.
A global leader of innovative solutions for portable and stationary grain handling, storage.
A global leader of innovative solutions for portable and stationary grain handling, storage.
PainCeptor Pharma is a pharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain. PainCeptor's therapeutic programs are concentrated on some of the most promising, novel, yet scientifically validated therapeutic targets within the PNS (peripheral nervous system). By focusing on modulating target receptors in the PNS, PainCeptor expects to enhance the efficacy and avoid the many detrimental side effects associated with today's pain drugs which act primarily in the CNS (central nervous system). PainCeptor's development pipeline includes two lead antagonist programs, targeting NGF/p75-TrkA and ASIC1a, and a third antagonist program targeting ASIC3.
BioAxone Therapeutic operates as a neuroscience company. The company specializes in the development and commercialization of proprietary technologies that target Rho signaling. It provides an experimental therapy for the treatment of neurological disorders. The company's product includes Cethrin for clinical trial for spinal cord injury. BioAxone Therapeutic was founded in 2000 and is based in Saint-Laurent, Canada.